Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances

• US 9,308,175 B2
• Filed: 09/14/2007
• Issued: 04/12/2016
• Est. Priority Date: 09/15/2006
• Status: Active Grant

• Current Assignee: Echo Pharmaceuticals B.V.
• Original Assignee: Echo Pharmaceuticals B.V.
• Inventors: Pellikaan, Hubert Clemens, Vermeulen, Pieter Sebastiaan, Bender, Johannes Caspar Mathias Elizabeth, Woerlee, Geert Feye
• Primary Examiner(s): Kassa, Tigabu
• Application Number:
  US12/441,342
• Publication Number:
  US 20100008985A1
• Time in Patent Office: 3,133 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

One aspect of the invention relates to a pharmaceutical dosage unit for sublingual, buccal, pulmonary or oral administration, said dosage unit having a weight of 20-500 mg and comprising 1-80 wt. % of a microgranulate that is distributed throughout a solid hydrophilic matrix; said microgranulate being characterized in that it: has a volume weighted average diameter of 5-100 m; contains at least 0.01 wt. %, preferably at least 0.1 wt. % of one or more water-insoluble pharmaceutically active substances; contains at least 10 wt. %, preferably at least 20 wt. % of an emulsifier component; and is capable of forming a micro-emulsion upon contact with saliva or water. The dosage units of the present invention achieve the inherent benefits of oral delivery while at the same time realizing a high transmucosal absorption rate of the cannabinoids contained therein. Other aspects of the present invention relate to the use of the aforementioned dosage units in the therapeutic or prophylactic treatment and to a process for the manufacture of said dosage units.

Claims

1. An oral pharmaceutical dosage unit comprising 1-80 wt. % of microgranulate particles distributed throughout a solid hydrophilic matrix, wherein the microgranulate particles have a volume weighted average diameter of 10-100 μ

m and consist of;

(a) at least 0.5 wt. % of one or more cannabinoids having a solubility in demineralised water of 37°

C. (neutral pH) of less than 200 mg/l;

(b) at least 50 wt. % of sugar fatty acid esters with an HLB of more than 7; and

, optionally

(c) an anti-oxidant, preservative, fat, wax, additional active substance and/or co-emulsifier,

wherein the one or more cannabinoids and sugar fatty acid esters together represent at least 80 wt. % of the microgranulate; and

wherein the pharmaceutical dosage unit forms a micro-emulsion upon contact with saliva or water.

2. The pharmaceutical dosage unit according to claim 1, wherein the dosage unit has between 0.5 and 10 wt. % of the cannabinoids.

3. The pharmaceutical dosage unit according to claim 1, wherein the dosage unit has 0.5-100 mg of the cannabinoids.

4. The pharmaceutical dosage unit according to claim 1, wherein the dosage unit has at least 10 μ

g of the cannabinoids.

5. The pharmaceutical dosage unit according to claim 1, wherein the microgranulate has at least 10 wt. % of the sugar fatty acid esters with an HLB of at least 10.

6. The pharmaceutical dosage unit according to claim 1, wherein the sugar fatty acid esters is a sucrose fatty acid ester.

7. The pharmaceutical dosage unit according to claim 6, wherein the sucrose fatty acid ester is 1-3 fatty acid residues per molecule.

8. The pharmaceutical dosage unit according to claim 1, wherein the cannabinoid is a tetrahydrocannabinoid.

9. The pharmaceutical dosage unit according to claim 1, wherein the solid hydrophilic matrix is 0.1-20 wt. % of a mucoadhesive agent selected from the group consisting of carbomers, cellulose derivatives, plant lectin, dextrin, hypromellose, chitosan, polyethylene oxide, alginate and combinations thereof.

10. The pharmaceutical dosage unit according to claim 8, wherein the dosage unit has 1-50 mg of the cannabinoids.

11. The pharmaceutical dosage unit according to claim 1, wherein the microgranulate has a volume weighted mean particle size of 10-180 μ

m.

12. The pharmaceutical dosage unit according to claim 1, wherein the dosage unit is a compressed tablet.

13. The pharmaceutical dosage unit according to claim 1, suitable for sublingual, buccal, or pulmonary delivery.

14. The pharmaceutical dosage unit according to claim 1 consisting of 5-80 wt. % of the microgranulate and 20-95 wt. % matrix forming components.